Background: Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Conclusions: These are the first multiresistant S. agalactiae with the bifunctional AAC(6 0 )-APH(2 00 ) enzyme to be reported in the UK for .10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.
Introduction
Streptococcus agalactiae [group B Streptococcus (GBS)] is an important agent of neonatal sepsis. In 2010, the UK incidence was 0.41 cases/1000 live births, with a growing number of adult septicaemias also recorded. 1 Most clinical isolates belong to clonal complexes (CCs) 1, 10, 17, 19 and 23, and, among these, CC17 is considered to have increased virulence potential. 2 Antibiotic resistance is not a major issue in the species. Penicillin remains the treatment of choice and resistance is extremely rare, though strains with reduced susceptibility are a growing problem in Japan. 3 Tetracycline resistance is frequent, 2 but is of limited clinical relevance, given that tetracyclines are contraindicated in neonates and their expectant mothers, who form the largest patient groups. Like all streptococci, GBS have low-level intrinsic resistance to gentamicin, reflecting poor uptake. High-level resistance, mediated by the bifunctional AAC(6 0 )-APH(2 00 ) enzyme that is prevalent in enterococci and staphylococci, has been reported on a few occasions in GBS in the UK 4 and France, 5 with some recent proliferation in Argentina, 6 but is considered still to be exceptional. Between 2001 and 2014, the BSAC Bacteraemia Surveillance Programme examined 1125 S. agalactiae from over 70 UK and Irish sites. In 2014, for the first time, we identified two isolates of this species with high-level gentamicin resistance. They were referred from separate hospitals and both also were unusually resistant to ciprofloxacin. The genomes of these organisms were sequenced to elucidate their relatedness and the genetic bases of their resistance phenotypes.
Materials and methods

Isolates and susceptibility testing
The collection strategy for the BSAC Bacteraemia Surveillance Programme has been described. 7 . On receipt by PHE, b-haemolytic streptococci are identified using the Streptococcal Grouping Latex kit (Pro-Lab Diagnostics, Bromborough, UK) and MICs are determined by BSAC agar dilution. 8 The two highly gentamicin-resistant isolates were collected in 2014 at separate hospitals 70 miles (112 km) apart: BSB14107 was from a 28-year-old woman and was isolated in the January; BSB14238 was from a 33-year-old man and was isolated in the April. We do not have clinical details for the patients.
Sequencing
Isolates were sequenced at PHE's Genomic Service Delivery Unit on an Illumina HiSeq 2500 platform using the Nextera XT sample preparation method. In silico MLST was performed using the mapping-based tool MOST, 9 with reference sequences downloaded from the S. agalactiae MLST database.
10 Antimicrobial resistance genes were detected using a locally curated database of resistance determinants and the in-house algorithm GeneFinder.
11 Short reads were assembled into contigs using SPAdes 12 and those carrying the gentamicin resistance determinant were identified by BLAST. Coding sequences were determined with Glimmer 13 with functions inferred from homology searches with BLAST. The genetic relatedness of the isolates was assessed by SNP analysis, as previously described. 14 
Results and discussion
Susceptibility
Among 3218 b-haemolytic streptococci collected from bacteraemic patients by the BSAC Bacteraemia Surveillance Programme from 2001 to 2014, 1125 were identified as S. agalactiae. MIC distributions for these are shown in Table 1 . Isolates BSB14107 and BSB14238 were the only two with high-level resistance to gentamicin and were among a small minority (7/1125) with high-level ciprofloxacin resistance. Both also were highly resistant to tetracycline, though this trait was highly prevalent in the whole collection, with MICs 16 mg/L for 82.4% of the isolates. Both retained normal susceptibility to b-lactams and vancomycin (Table 1) . BSB14107 was highly resistant to both erythromycin and clindamycin (MICs .128 mg/L); BSB14238 had low-level resistance to erythromycin (MIC 2 mg/L), but remained fully susceptible to clindamycin (MIC 0.12 mg/L).
Sequencing and strain characterization
Based on in silico MLST, using whole-genome sequences, both resistant isolates belonged to the ST19 clone, which occurs internationally. Nevertheless, their sequences differed by at least 934 SNPs, indicating them to be distinct. The phenotypes of both isolates (Table 1) could be explained by the acquired resistance genes or mutations identified. Both carried aac(6 0 )-aph(2 00 ), explaining high-level gentamicin resistance; both also had chromosomal gyrA[81:S-L];parC[79:S-Y] mutations, explaining high-level ciprofloxacin resistance. Furthermore, both had tet(M), accounting for tetracycline resistance; this was embedded in the same position in Tn916-like elements in both strains and was unlinked to aac(6 0 )-aph(2 00 ). BSB14107 additionally had mef(E), erm(B), msr(D), lsa(E) and lnu(B), all of which contribute to high-level macrolide and lincosamide resistance, as observed in this strain. BSB14238 had erm(TR), explaining low-level macrolide resistance; it also carried lnu(C), but this gene does not reliably cause clindamycin resistance in streptococci 15 and so is not discordant with observed susceptibility.
The aac(6 0 )-aph(2 00 ) gene was transposon borne in both isolates, but the genetic environments (Figure 1 ) differed between the two organisms. In BSB14107 the arrangement most closely resembled that previously described from S. agalactiae SGB76, 16 though this strain did not carry aac(6 0 )-aph(2 00 ). Specifically, aac(6 0 )-aph(2 00 ) was located on the same contig as a known mobile element carrying aadE and lnu(B) along with the spectinomycin adenyltransferase determinant, spc; however, no direct association with known mobile elements was apparent for aac(6 0 )-aph(2 00 ) itself (Figure 1a) . In BSB14238, aac(6 0 )-aph(2 00 ) was linked to the insertion element IS256, as previously described in Tn3706 Highly gentamicin-resistant S. agalactiae JAC from S. agalactiae isolated in France in 1987 17 and in Tn4001 from staphylococci. 18 However, only the upstream copy of IS256 was confirmed; downstream of aac(6 0 )-aph(2 00 ) we found only the end of the putative second IS256 copy; failure to detect the entire element probably reflects problems inherent in resolving repeats in short-read assemblies.
Conclusions
In summary, S. agalactiae with high-level gentamicin resistance mediated by the bifunctional AAC(6 0 )-APH(2 00 ) enzyme have (re-)emerged in the UK. It is unknown whether the isolates were imported or whether they acquired their resistance transposons locally. Isolates with this mechanism were reported in the country in 2002, 4 but have not, to our knowledge, been recorded subsequently. Despite belonging to ST19 and sharing exceptional fluoroquinolone resistance, the present isolates and their resistance transposons were distinct from each other; that in BSB14107 was distinct from any previously found in GBS.
Despite the organisms' multiresistance, and their evident ability to cause infection in the source patients, their wider clinical significance is uncertain. UK guidelines 19 advocate empirical penicillin plus gentamicin for neonatal sepsis and similar regimens are widely used internationally. The general view in the UK is that the penicillin covers against GBS whilst the gentamicin covers against Enterobacteriaceae, which are the other likely pathogens in the setting. If this view is correct, high-level gentamicin resistance in GBS will be of little significance. A counter view is that gentamicin may potentiate penicillins in S. agalactiae bacteraemia, as in streptococcal endocarditis. In this case high-level resistance would be predicted to abrogate this synergy, potentially impacting upon outcomes. There is, however, scant clinical evidence to support this latter view, and a recent in vitro analysis found that gentamicin only gave a small acceleration of penicillin-mediated killing, Figure 1 . Genetic support of aac(6 0 )-aph(2 00 ) in (a) S. agalactiae BSB14107 and (b) S. agalactiae BSB14238. Mobile elements are shown in red, resistance determinants in blue, other known genes in green and hypothetical and unknown genes in black. Homology between sequences is indicated in grey. The element from BSB14017 most closely resembled that previously described from S. agalactiae SGB76, 16 though this did not carry aac(6 0 )-aph(2 00 ); that from BSB14238 was related to Tn3706 and Tn4001, which have been described carrying aac(6 0 )-aph(2 00 ) in S. agalactiae and Staphylococcus aureus respectively. 17, 18 This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
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without convincing synergy. 20 A separate and less debatable risk is that GBS may become a vector of transposons encoding AAC(6 0 )-APH(2 00 ), facilitating its widening dissemination.
